blank

develop engineered T cell Therapy against solid tumors by rewriting biology and medicine with data-driven computing

About SYNLICO

We are integrating three distinct while trending fields of biology: system biology, single-cell bioinformatics, and synthetic biology.

By combining the state-of-the-art development in these fields, we are building an in silico technology platform that would change the drug discovery process from a screening based to a computation centric iterative engineering process.

The platform will enable us to target T cells-solid tumors interactions across scales, especially to address the complexity and heterogeneity of the tumor microenvironment.

blank
blank

Science

Key Problems that Hinder CAR-TTherapy Against Solid Tumors

blank

Disconnectionof CAR-T design with TME heterogeneity and complexity

blank

Unpredictableeffect of design cross different scale of immune response

blank

Trial and errorscreening-based drug discovery process for T cell therapy

Thus far, there have been NO impressive results from the use of CAR T cells in solid tumors, even though many companies are actively engaged in its R&D.

OurSolution

blank

Develop deep insights into cellular heterogeneity, and heterogeneity of tumor microenvironment.

blank

Tailor drug design addressing TME heterogeneity and complexity in combination of cell-cell communication and interaction information.

blank

In silico lab conducted by interrogating model, and continuously improved machine learning platform with additional knowledge and data.

TEAM

We are a team of Innovation and Passion

blank

Jingwei Lu, Ph.D.

Founder & CEO

Read More

Jingwei Lu, Ph.D.

With a strong background in the engineered T cell therapy industry, Dr. Lu has proven to be a leading innovator in both R&D and business development. Before starting Synlico Inc, Dr. Lu was a key player in the R&D department at Eureka Therapeutics, where he played a crucial role in developing the next generation of engineered T cell platforms. His impressive portfolio includes total over 50 patents (include pending) worldwide in engineered T cell therapy. These 6 US patents (4 granted) as the first inventor on engineered T cell therapy platform technology, as well as 2 US patents (1 granted) as a co-inventor. These patents showcase Dr. Lu’s expertise in the field. In addition to his research contributions, Dr. Lu has also led Eureka’s efforts on technology and market analysis and corporate external cooperation at the Strategic Alliances department. Dr. Lu has been an active member of the American Association for Cancer Research (AACR) since 2014.
Dr. Lu holds a Ph.D. in Molecular, Cellular and Developmental Biology from the Ohio State University and a B.S. in Physics from Peking University, China.

blank

Xiuping Li, CPA

Director of Finance

Read More

Xiuping Li, CPA

Ms. Li is a driving force behind our financial strategy and operations. With years of experience in SOX compliance, risk assessment and control, internal auditing, and consulting, Ms. Li has a track record of success in leading key projects and helping clients, from startups to Fortune 500 companies, reach their financial goals. Ms. Li has been a Certified Public Accountant (C.P.A.) in the US since 2016. With her wealth of experience, Ms. Li is a invaluable asset to our team and a key player in driving our success.
Ms. Li holds a B.S. in Business Administration from the Ohio State University.

blank

Yuxin Chen, Ph.D.

Scientist - System Biology

Read More

Yuxin Chen, Ph.D.

Dr. Yuxin Chen is a leading expert in gene regulatory networks and tumor evolution, with a wealth of experience in these cutting-edge fields. He received his Ph.D. under the guidance of renowned molecular evolution biologist Prof. Chung-I Wu. After honing his skills and gaining valuable insights after spending one year as visiting scholar at Yale, Dr. Chen joined the lab of eminent system biologist Prof. James Ferrell at Stanford University, where he spent four years as a postdoc conducting innovative research on intercellular antiviral cell signaling. Dr. Chen has made significant contributions to the scientific community through his numerous publications in leading journals. His strong background and expertise make him an invaluable asset to any research team.
Dr. Chen holds a Ph.D. in Biochemistry & Molecular Biology and a B.S. in Biology from Sun Yat-sen University in China.

blank

Aaron Wong, Ph.D.

Scientist - Bioinformatics, Single Cell

Read More

Aaron Wong, Ph.D.

Dr. Wong is a highly accomplished scientist with strong background in bioinformatics and single cell transcriptomics especially in lung research. He received his Ph.D under the guidance of renowned researcher Dr. Mingyao Liu at the University of Toronto, where he developed the world first catalog of donor and recipient cell-type specific responses to injury during transplantation at single cell level. Dr. Wong has also developed innovative techniques such as the world first hypothermic dissociation protocol for adult human lung tissue. Dr. Wong has made significant contributions to the field through his numerous publications in leading journals, and is a valuable asset to Synlico’s research team
Dr. Wong holds a Ph.D. in Computational Biology from University of Toronto and a B.S. in Molecular Biology and Genetics with honors from McMaster University in Canada.

blank

Shiling Guo, M.A.

Investor Relations Manager

Read More

Shiling Guo, M.A.

With 15 years of financial services, due diligence, and operations management experience, Ms. Guo is a seasoned professional with a strong background in the industry. Prior to joining Synlico, Ms. Guo served as the Head of Retail Banking Customer Due Diligence at Standard Chartered Global Business Services Co., where she championed business migration projects and led the team to perform post-transaction due diligence investigations. Before that, Ms. Guo held the position of Operations Manager at HSBC, overseeing the delivery of financial services in four cities. Her extensive experience makes her a valuable asset to our team.
Ms. Guo holds M.A. in Financial Integrity from Case Western Reserve University, L.L.B. in International Business Law and B.A. in English for International Business Management from Guangdong University of Foreign Studies.

blank

Tunc Morova, Ph.D.

Data Scientist - Bioinformatics

Read More

Tunc Morova, Ph.D.

Dr. Tunc Morova has over 7 years of field experience in bioinformatics and data science, with an excellent track record of publications in high impact journals. He received his Ph.D under joined guidance of Professor Faraz Hach and Nathan Lack at Vancouver Prostate Centre, University of British Columbia, Canada, where he designed a novel variant-aware version of STARRseq method and created the first functional map of Anderogen Receptor enhancers using STARRseq experimental method. Dr. Morova has strong experience in developing scalable and streamlined pipelines to process various bioinformatics data and is a valuable asset to our research team.

Dr. Morova holds a Ph.D in bioinformatics from University of British Columbia, Canada, an M.S. in Biomedical Science and Engineering from Koc University, Turkey, and a B.S. in Bioengineering from Marmara University, Turkey.

Investor

If you are interested in more information about our company, please send your inquiry to investor@synlico.com.

Career

Welcome to join our team

We welcome scientists with strong academic backgrounds regardless of industry experience to join our team to make a difference and change the current status quo.

contact us

Talent Recruitment

General Inquiry

Address: Synlico Inc.